ISRCTN58259979已完成2 期
Double-blind, randomized, placebo-controlled trial of alpha-lipoic acid for fibromyalgia
Physicians Services Incorporated Foundation0 个研究点目标入组 27 人开始时间: 2016年3月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 27
研究概览
简要总结
2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/28351829 2021 results in https://pubmed.ncbi.nlm.nih.gov/32773602/ (added 21/05/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 and older
- •2. Meeting the 2010 American College of Rheumatology diagnostic criteria for fibromyalgia
- •3. Experienced at least moderate daily pain (Numerical Rating Scale = 4/10) for at least 3 months prior to study entry
- •4. AST (aspartate aminotransferase)/ALT (alanine aminotransferase) no greater than 20% the upper limit of normal
- •5. Serum creatinine no greater than 50% the upper limit of normal
- •6. Necessary abilities, visual acuity and language skills for pain diary completion and telephone communication with study nurses
排除标准
- •1. Any major organ system disease
- •2. Major poorly controlled psychiatric disorder
- •3. Severe depression or suicidal ideation
- •4. Active substance abuse disorder
- •5. Lactose intolerance
- •6. Hypersensitivity to ALA
- •7. Painful condition more than 50% as severe as their fibromyalgia pain
- •8. Unwillingness to use a highly effective form of contraception (women of childbearing potential)
研究者
相似试验
已完成
不适用
Studying the impact of Lorazepam on approach/avoidance behaviour in healthy individualsISRCTN12590498Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)60
已完成
2 期
Study to evaluate the safety and efficacy of CCX168 in subjects with renal vasculitis on background cyclophosphamide treatmentRenal VasculitisCirculatory SystemRenal vasculitisISRCTN53663626ChemoCentryx, Inc. (USA)60
已完成
2 期
A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosisTuberous sclerosisNervous System DiseasesISRCTN09739757Cardiff University (UK)38
已完成
1 期
A dose-escalating clinical trial with KH176Mitochondrial diseaseISRCTN43372293Khondrion30
已完成
不适用
A trial of Exenatide for the treatment of moderate severity Parkinson's diseaseTopic: Dementias and Neurodegenerative Diseases Research NetworkSubtopic: Parkinson?s DiseaseDisease: Parkinson's diseaseNervous System DiseasesParkinson diseaseISRCTN75891427niversity College London (UK)60